Aktie A3C9K5 PARDES BIOSCIENCES, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Pardes Biosciences, Inc.

Aktien

A3C9K5

US69945Q1058

PRDS

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Pardes Biosciences Goes Public Following Merger With Blank Check Firm FS Development
FS II : Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19 - Form 8-K
PARDES BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
FS Development Corp. II(NasdaqCM:FSII) dropped from NASDAQ Composite Index
PARDES BIOSCIENCES, INC. : Regulation FD Disclosure (form 8-K)
FS DEVELOPMENT CORP. II : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)
Pardes Biosciences, Inc. completed the acquisition of FS Development Corp. II from FS Development Holdings II, LLC, Daniel Dubin, Owen Hughes, Deepa Pakianathan, and others in a reverse merger transaction.
FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections
FS II : FSII and Pardes Biosciences Move Towards Merger with the Goal of Tackling COVID-19 Via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections - Form 8-K
FS DEVELOPMENT CORP. II : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
FS II : Material Event - Form 8-K
FS DEVELOPMENT CORP. II : Other Events (form 8-K)
FS Development Corp. II Registration Statement for Merger with Pardes Declared Effective by SEC
FS Development II : Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021 - Form 8-K
FS DEVELOPMENT CORP. II : Other Events, Financial Statements and Exhibits (form 8-K)
FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021
FS DEVELOPMENT CORP. II Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q/A)
FS DEVELOPMENT CORP. II : Non-Reliance on Previous Financials, Audits or Interim Review (form 8-K)
FS DEVELOPMENT CORP. II : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
FS DEVELOPMENT CORP. II Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3C9K5 Aktie
  4. Nachrichten Pardes Biosciences, Inc.
  5. Andere Sprachen